Introduction: COVID-19 infection has spread with the development of the pandemic and is transmitted by respiratory droplets. The level of protection of vaccines administered together with the COVID-19 vaccine is the subject of research. We aimed to examine intensive care patients with Sinovac and Biontech vaccines.
Material and Method: After the approval of the ethics committee, 45 patient data were included in our study. Vaccination status in intensive care units was examined and patients were grouped into Sinovac and Biontech. Age, sex, comorbid conditions, and mortality rates were compared statistically. With this comparison, the effects on mortality and clinical features were evaluated.
Results: Forty-five patients between March 31 and December 31, 2021 were included in the study. In these patients, patients who received 2 doses of vaccine in the period before hospitalization according to the intensive care evaluation criteria were examined. Mortality rates were higher in patients who received 2 doses of Sinovac vaccine in patients hospitalized in the intensive care unit compared to those who received 2 doses of Biontech vaccine.
Conclusion: It was observed that the vaccination status of patients who were vaccinated with COVID-19 and taken to the intensive care unit affected mortality. Studies with larger numbers of patients are needed.
Mullard A. COVID-19 vaccine development pipeline gears up. Lancet. 2020; 395: 1751–1752.
Matrajt L, Eaton J, Leung T, Brown ER. Vaccine optimization for COVID-19: Who to vaccinate first?. Science Advances. 2021; 7(6): eabf1374.
Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart SP, et al. Phase 1/2 study to describe the safety and immunogenicity of a COVID-19 RNA vaccine candidate (BNT162b1) in adults 18 to 55 years of age: interim report. medRxiv. 2020.
Sharma O, Sultan AA, Ding H, Triggle CR. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. Frontiers in Immunology. 2020; 11: 2413.
Dou E. As China nears a coronavirus vaccine, bribery cloud hangs over drugmaker Sinovac. [Internet] 2020 The Washington Post. [cited 2020 December 6] Available from: https://www.washingtonpost.com/world/asia_pacific/coronavirus-vaccine-china-bribery-sinovac/2020/12/04/7c09ae68-28c6-11eb-9c21-3cc501d0981f_story.html
Lu L, Mok BW, Chen LL, Chan JM, Tsang OT, Lam BH. Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients. Clin Infect Dis. 2021: ciab1041.
Burgos RM, Badowski ME, Drwiega E, Ghassemi S, Griffith N, Herald F, et al. The race to a COVID-19 vaccine: Opportunities and challenges in development and distribution. Drugs in Context. 2021; 10.
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383(27): 2603-2615.
Walsh EE, Frenck RW Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med. 2020; 383(25): 2439-2450.
Fadlyana E, Rusmil K, Tarigan R, Rahmadi AR, Prodjosoewojo S, Sofiatin Y, et al. A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia. Vaccine. 2021; 39(44): 6520-6528.
Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jiang Z, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021; 21(6): 803-812.
Zhang Y, Zeng G, Pan H. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2020.
Sauer K, Harris T. An effective COVID-19 vaccine needs to engage T cells. Front Immunol. 2020; 11.
Polack FP, Thomas SJ, Kitchin N, et al.; C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020; 383: 2603–15.
Sadoff J, ENSEMBLE Study Group. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021; 384: 2187–201.